Loading clinical trials...

Parathyroid Adenoma Detection With Rubidium-82 Imaging | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

Parathyroid Adenoma Detection With Rubidium-82 Imaging

Parathyroid Adenoma Detection With Rubidium Chloride Imaging: A Proof-of-Concept Study

NCT07099404•Matthieu Pelletier-Galarneau, MD MSc

View on ClinicalTrials.gov

Summary

Assess the uptake of rubidium-82 in parathyroid adenomas.

Detailed Description

Parathyroid adenomas demonstrate uptake of rubidium-82 chloride and can be detected with PET imaging. The investigators aim to describe the uptake pattern of rubidium-82 chloride in parathyroid adenomas as well as compare the uptake pattern of rubidium-82 chloride to that of 18F-fluorocholine in patients with parathyroid adenoma.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥ 18y
•2. Ability to undergo imaging logistics
•3. Ability to provide informed consent
•4. Biochemical evidence of primary hyperparathyroidism
•5. Documented parathyroid adenoma on prior 18F-fluorocholine imaging

Exclusion Criteria

•1. Normocalcemic primary hyperparathyroidism
•2. Breastfeeding or pregnancy
•3. Claustrophobia or inability to undergo imaging logistics
•4. Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study

Locations (2)

Montreal Heart Institute

Montreal, Quebec, Canada

Montreal Jewish General Hospital

Montreal, Quebec, Canada

Key Dates

Start Date

November 1, 2025

Primary Completion Date

September 1, 2027

Completion Date

September 1, 2028

Last Updated

August 22, 2025

Enrollment

ESTIMATED participants

Conditions

Parathyroid AdenomasHyperparathyroidism, Primary

Interventions

PET/CT imaging with rubidium-82

OTHER

Contacts

Matthieu Pelletier-Galarneau, MD MSc

CONTACT

514-376-3330 matthieu.pelletier-galarneau@icm-mhi.org

Pelletier-Galarneau

CONTACT

WHITE CAP: Intra-operative Parathyroid Tissue Sensor (PTS)-Guided Assessment of Parathyroid Viability and Surgical Decision-Making

NCT07043010

Hyperparathyroidism, PrimaryParathyroid Neoplasms+2 more

View study

NOT_YET_RECRUITING

The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism

NCT05556499

Hyperparathyroidism, PrimaryOsteoporosis+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Parathyroid Adenoma Detection With Rubidium-82 Imaging

Inclusion Criteria

Exclusion Criteria

WHITE CAP: Intra-operative Parathyroid Tissue Sensor (PTS)-Guided Assessment of Parathyroid Viability and Surgical Decision-Making

The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism

Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.